Literature DB >> 12833464

Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.

Hung-Wei Pan1, Yueh-Hsing Ou, Shian-Yang Peng, Shu-Hsian Liu, Po-Lin Lai, Po-Hwaung Lee, Jin-Chuan Sheu, Chi-Ling Chen, Hey-Chi Hsu.   

Abstract

BACKGROUND: Intrahepatic metastasis via portal vein spread is an important feature and a crucial unfavorable prognostic factor of hepatocellular carcinoma (HCC). To identify the molecular factors for tumor progression, the authors used differential display (DD) to analyze aberrant gene expression in HCC. The goal of the current study was to elucidate the clinicopathologic and prognostic significance of osteopontin (OPN) in HCC progression.
METHODS: OPN mRNA levels, which were increased preferentially in HCC in a DD assay and verified with Northern blotting, were measured in 240 surgically removed, unifocal, primary HCCs using the reverse transcription-polymerase chain reaction at the exponential phase. OPN mRNA expression was correlated with clinicopathologic features, particularly portal vein invasion, early tumor recurrence, and prognosis.
RESULTS: Osteopontin mRNA was overexpressed in 133 tumors (55%). The OPN overexpression was associated closely with alpha-fetoprotein elevation (P = 0.001), p53 mutation (P = 0.021), larger tumors (P = 0.002), high-grade HCC (P < 0.001), late-stage HCC (P < 0.001), early tumor recurrence and/or metastasis (P = 0.003), and a lower 10-year survival rate (P = 0.00013). Multivariate analysis revealed that tumor stage and early tumor recurrence were crucial prognostic factors. In early-stage HCC, which has no vascular invasion and a lower early tumor recurrence than late-stage HCC, OPN mRNA overexpression predicted a higher early recurrence rate (P = 0.003).
CONCLUSIONS: OPN mRNA overexpression was correlated closely with high-grade, late-stage, and early tumor recurrence, which lead to poorer prognosis. Osteopontin overexpression might serve as an unfavorable prognostic factor and a useful marker for predicting early recurrence in early-stage HCC. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11487

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833464     DOI: 10.1002/cncr.11487

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  90 in total

1.  Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.

Authors:  Jason LeGrand; Eun Sung Park; Hongyang Wang; Shalu Gupta; James D Owens; Patrick J Nelson; Wendy DuBois; Thomas Bair; Siegfried Janz; J Frederic Mushinski
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  Identification of osteopontin as a novel marker for early hepatocellular carcinoma.

Authors:  Sufen Shang; Amelie Plymoth; Shaokui Ge; Ziding Feng; Hugo R Rosen; Suleeporn Sangrajrang; Pierre Hainaut; Jorge A Marrero; Laura Beretta
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

3.  Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells.

Authors:  Fan Lin; Yuyuan Li; Jie Cao; Shaofeng Fan; Jifeng Wen; Guanghui Zhu; Hong Du; Yanxiao Liang
Journal:  Mol Biol Rep       Date:  2010-12-29       Impact factor: 2.316

4.  Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Lin Zhong; Mu-Jian Teng; Jun-Wei Fan; Hua-Mei Tang; Jun-Yi Wu; Hong-Yuan Chen; Zhao-Wen Wang; Guo-Qiang Qiu; Zhi-Hai Peng
Journal:  Mol Oncol       Date:  2012-04-17       Impact factor: 6.603

5.  Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis.

Authors:  Holger G Hass; Oliver Nehls; Juergen Jobst; Andrea Frilling; Ulrich Vogel; Stephan Kaiser
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

6.  Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.

Authors:  Alison L Allan; Rosamma George; Sharon A Vantyghem; Mark W Lee; Nicole C Hodgson; C Jay Engel; Ron L Holliday; David P Girvan; Leslie A Scott; Carl O Postenka; Waleed Al-Katib; Larry W Stitt; Toshimitsu Uede; Ann F Chambers; Alan B Tuck
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

Review 7.  A decade's studies on metastasis of hepatocellular carcinoma.

Authors:  Zhao-You Tang; Sheng-Long Ye; Yin-Kun Liu; Lun-Xiu Qin; Hui-Chuan Sun; Qin-Hai Ye; Lu Wang; Jian Zhou; Shuang-Jian Qiu; Yan Li; Xue-Ning Ji; Hu Liu; Jing-Ling Xia; Zhi-Quan Wu; Jia Fan; Zeng-Chen Ma; Xin-Da Zhou; Zhi-Ying Lin; Kang-Da Liu
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-18       Impact factor: 4.553

8.  Can combination of osteopontin and peritumor-infiltrating macrophages be a prognostic marker of early-stage hepatocellular carcinoma?

Authors:  Yoo Jin Lee; Byoung Kuk Jang
Journal:  Hepatobiliary Surg Nutr       Date:  2014-04       Impact factor: 7.293

Review 9.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

10.  Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH.

Authors:  Jin-Cai Wu; Bing-Sheng Sun; Ning Ren; Qing-Hai Ye; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.